Integra LifeSciences Holdings has seen a sharp reset in recent years, yet the shares have climbed back to US$14.12, which raises a clear question about what its cash flows really support today. After such a mixed share price path, investors are increasingly asking whether the current valuation is still grounded in the money the business can generate over time. Over the past 5 years the stock has fallen 79.3%. This puts the focus squarely on whether the current US$14.12 price is now aligned...
PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciences Integra LifeScience
Integra LifeSciences reported third quarter 2026 sales of US$411.18 million and net income of US$14.85 million, with diluted earnings per share from continuing operations of US$0.19 compared with a diluted loss a year earlier. The company paired this return to profitability with fresh fourth quarter 2026 revenue guidance and plans to showcase key neurosurgery technologies at a major clinical meeting. Together these developments highlight both current operating traction and an effort to keep...
Integra LifeSciences Holdings: Why Third Quarter Earnings Matter Now Integra LifeSciences Holdings (IART) has drawn fresh attention after third quarter 2026 results showed sales of US$411.18 million and a move from a prior net loss to US$14.85 million in profit. That earnings swing has landed in a period where Integra LifeSciences Holdings’ share price return has been volatile. The stock closed at US$13.61 after a 1 day share price return of 6.75% and a 7 day share price return of 12.48%, yet...
Detailed price information for Baxter International (BAX-N) from The Globe and Mail including charting and trades.
Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.
Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.
Integra LifeSciences cut its 2026 financial guidance after a July flood disrupted its Cincinnati facility and negatively impacted revenue.
Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 15.3% in the morning session after the company released preliminary third-quarter 2026 results and reduced its full-year revenue and adjusted EPS guidance due to operational disruption caused by a July 2026 flood at its Cincinnati facility.
Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654...
Integra LifeSciences (IART:NASDAQ) shares are down about 11% this morning (trading at about $14) after the company cut its 2026 guidance and launched a $600 million term loan. The July flood at its Cincinnati plant is a major driver of the cut, though Integra said the new guidance also reflects updated assumptions for the broader business.
Integra LifeSciences (IART) stock drops after a flood-hit facility prompts the company to cut its guidance to a level below consensus. Read more here.
This is the newest page. Registered accounts read further back.